ALD technology, with its atomic-level precision thin film deposition capability, has demonstrated unique application value in the pharmaceutical field. Currently, it mainly focuses on two directions: optimization of drug delivery systems and functionalization of medical consumables.

1. Precise modification of nano-drug delivery systems

ALD can deposit biocompatible films (such as Al₂O₃, SiO₂) on the surface of drug carriers (such as nanoparticles, liposomes), achieving:

o controlled-release performance improvement: By adjusting the film thickness (1-10 nm), the drug release rate can be controlled. For instance, after doxorubicin nanoparticles are coated with ALD, their half-life is extended by 2-3 times, reducing toxicity to normal cells.

o Enhanced stability: A dense protective layer is formed on the surface of protein drug carriers, solving their problems of easy degradation and short half-life. For example, after insulin nanocapsules are treated with ALD, their stability in the gastric juice environment is increased by more than 40%.

2. Surface functionalization of medical consumables

For implantable medical devices (such as stents and artificial joints), antibacterial coatings deposited by ALD (such as TiO₂, Ag-based films) can inhibit bacterial adhesion and biofilm formation, reducing the risk of postoperative infection. For example, after the coronary artery stent was coated with ZnO nano-coating deposited by ALD, the antibacterial rate reached 99%, and the biocompatibility met the ISO 10993 standard. In addition, ALD technology can modify the surface of microfluidic chip channels, improve their hydrophilicity or hydrophobicity, and enhance the efficiency of drug screening.

Ii. Market Size and Growth Drivers

At present, the application of ALD in the pharmaceutical field is still in the transition stage from research and development to industrialization. The global market size is expected to be approximately 120 million US dollars in 2024, accounting for 3% to 5% of the total ALD equipment market, but the growth potential is significant.

Technology-driven: The demand for "precision medicine" in the pharmaceutical industry has driven the development of nano-drug delivery technology, and ALD is the only feasible technology for achieving atomic-level modification of carrier surfaces. According to industry research, the number of nanomedicine research and development projects adopting ALD technology has been growing at an annual rate of over 25%.

Policy support: The US FDA has included "advanced manufacturing technology" in the accelerated approval channel for drugs. ALD, as a representative of atomic-level manufacturing, its related processes can shorten the drug market launch cycle. China's "14th Five-Year Plan" for the development of the pharmaceutical industry also proposes to support the application of "micro-nano manufacturing technology in high-end preparations", indirectly promoting the demand for ALD equipment.

Iii. Competitive Landscape and Current Status of the Industrial Chain

<s:1> International dominance, domestic start-up: Currently, the market for ALD equipment used in the pharmaceutical industry is dominated by international manufacturers such as Applied Materials (AMAT) and ASM. Their equipment is compatible with the deposition of organic precursors (such as Al(CH₃)₃) and biocompatible materials, meeting GMP cleanliness requirements. Domestic manufacturers such as MicroAdmittance Nano and Toprun Technology have launched laboratory-grade ALD devices, but they have not yet entered the mass production stage of pharmaceutical enterprises.

Insufficient industrial chain collaboration: The cooperation between ALD equipment manufacturers and pharmaceutical enterprises still mainly focuses on "customized R&D", lacking standardized solutions. For instance, pharmaceutical companies such as Pfizer and Roche have jointly developed ALD modification processes for mRNA vaccine vectors with equipment manufacturers through a joint research and development model, but have not yet achieved large-scale procurement.

Iv. Challenges and Breakthrough Directions

1. Technical barriers and cost constraints

o Process compatibility: The pharmaceutical field requires the use of biocompatible precursors (such as organosilanes), while the existing ALD equipment is mostly designed for the semiconductor industry. It is necessary to modify the reaction chamber and gas delivery system to avoid chemical contamination.

High cost: The price of a single laboratory-grade ALD device exceeds 5 million yuan, and its single processing capacity is small (usually ≤ 100mg of drug-loaded particles), which is difficult to meet the large-scale production demands of the pharmaceutical industry.

2. The regulatory and verification cycle is long

Ald-modified drug carriers need to pass strict biosafety verifications (such as long-term toxicity and immunogenicity tests), and the verification cycle usually exceeds three years, which leads to a slower technology implementation speed compared to fields such as semiconductors and new energy.

V. Future Trend Outlook

1. Application scenario expansion

In addition to drug delivery, the application of ALD in the extraction of active ingredients from traditional Chinese medicine (such as modifying the surface of adsorbents to enhance separation efficiency) and the consistency evaluation of generic drugs (regulating drug dissolution through film modification) will be gradually explored, further opening up market space.

2. Equipment customization and localization

Domestic equipment manufacturers are expected to enter niche markets through "differentiated competition", such as developing fluidized bed ALD equipment suitable for powdered drug carriers or integrating online characterization functions (such as QCM film thickness monitoring) for pharmaceution-specific systems, gradually breaking international monopolies.

3. Market size forecast

It is expected that by 2030, with the accelerated commercialization of nanomedicines and the increasing demand for functionalization of medical consumables, the market size of ALD equipment in the pharmaceutical field will exceed 1 billion US dollars, with a compound annual growth rate of 18% to 22%, becoming another application field of ALD technology after semiconductors, new energy, and new displays.

Vi. Conclusion

The market prospects of ALD atomic layer deposition equipment in the pharmaceutical field are promising in the long term, but it faces technical and cost challenges in the short term. Its core value lies in addressing the pain points of "precision and functionalization" in nanomedicines and high-end medical consumables, and the key to breaking through lies in customized equipment upgrades, biocompatibility process development, and collaborative innovation in the industrial chain. With the maturation of technology and the improvement of regulations, ALD is expected to become the core technical support for "micro-nano manufacturing" in the pharmaceutical industry.